CEMP To Face FDA Panel, RIGL On A High, FDA Nod For Erelzi, KPTI Awaits STORM

Shares of Karyopharm Therapeutics Inc. (KPTI) soared over 36% on Tuesday after the company said it will provide an overview of top-line results from its Phase 2b study for oral Selinexor in multiple myeloma, dubbed STORM, on September 6, 2016.

from RTT - Biotech http://ift.tt/2bAN5Do
via IFTTT